BACKGROUND: Research on hot flashes (HFs) after the diagnosis and treatment of breast carcinoma (BC) is scarce. To our knowledge, this research represents the second study of HF prevalence and severity in women with BC and the first study of 1) correlates of HF prevalence and severity, 2) use of HF management strategies, and 3) the relation between HFs and quality of life (QOL) among women with BC. METHODS: Eligible women (n = 136) participated in structured telephone interviews. RESULTS: Of the 114 postmenopausal women interviewed, 65% reported HFs, with 59% of women with HFs (n = 74) rating the symptom as severe. Multivariate analysis revealed that 1) HFs were most common in women with a high school education or less and those who were younger at diagnosis and 2) HFs were most severe in women with a higher body mass index, those who were younger at diagnosis, and those receiving tamoxifen. Among women with HFs, 37% were not using any HF management strategies and 63% expressed interest in learning more regarding > or = 1 strategy. HFs marginally were related to decreased mental and physical QOL using the SF-12 Health Survey (P < 0.10). CONCLUSIONS: The results of the current study significantly contribute to knowledge regarding HFs in women with BC and support the need for carefully controlled clinical trials evaluating interventions for relieving HFs in this population.
BACKGROUND: Research on hot flashes (HFs) after the diagnosis and treatment of breast carcinoma (BC) is scarce. To our knowledge, this research represents the second study of HF prevalence and severity in women with BC and the first study of 1) correlates of HF prevalence and severity, 2) use of HF management strategies, and 3) the relation between HFs and quality of life (QOL) among women with BC. METHODS: Eligible women (n = 136) participated in structured telephone interviews. RESULTS: Of the 114 postmenopausal women interviewed, 65% reported HFs, with 59% of women with HFs (n = 74) rating the symptom as severe. Multivariate analysis revealed that 1) HFs were most common in women with a high school education or less and those who were younger at diagnosis and 2) HFs were most severe in women with a higher body mass index, those who were younger at diagnosis, and those receiving tamoxifen. Among women with HFs, 37% were not using any HF management strategies and 63% expressed interest in learning more regarding > or = 1 strategy. HFs marginally were related to decreased mental and physical QOL using the SF-12 Health Survey (P < 0.10). CONCLUSIONS: The results of the current study significantly contribute to knowledge regarding HFs in women with BC and support the need for carefully controlled clinical trials evaluating interventions for relieving HFs in this population.
Authors: Danielle B Tometich; Catherine E Mosher; Adam T Hirsh; Kevin L Rand; Shelley A Johns; Marianne S Matthias; Samantha D Outcalt; Bryan P Schneider; Lida Mina; Anna Maria V Storniolo; Erin V Newton; Kathy D Miller Journal: Support Care Cancer Date: 2018-05-07 Impact factor: 3.603
Authors: Laxmi A Kondapalli; Katherine E Dillon; Mary D Sammel; Anushree Ray; Maureen Prewitt; Jill P Ginsberg; Clarisa R Gracia Journal: Qual Life Res Date: 2013-07-24 Impact factor: 4.147
Authors: Gary Elkins; Joel Marcus; Vered Stearns; Michelle Perfect; M Hasan Rajab; Christopher Ruud; Lynne Palamara; Timothy Keith Journal: J Clin Oncol Date: 2008-09-22 Impact factor: 44.544
Authors: Young Ju Jeong; Young Sun Park; Hyo Jung Kwon; Im Hee Shin; Jin Gu Bong; Sung Hwan Park Journal: J Altern Complement Med Date: 2013-02-05 Impact factor: 2.579
Authors: Julie L Otte; Janet S Carpenter; Kathleen M Russell; Silvia Bigatti; Victoria L Champion Journal: J Pain Symptom Manage Date: 2010-01-18 Impact factor: 3.612
Authors: M Kay Garcia; Leslie Graham-Getty; Robin Haddad; Yisheng Li; Jennifer McQuade; Richard T Lee; Michael Spano; Lorenzo Cohen Journal: Cancer Date: 2015-08-17 Impact factor: 6.860